Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $117.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective boosted by TD Cowen from $115.00 to $117.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also recently commented on the company. Royal Bank Of Canada cut their price target on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a research note on Thursday. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Stifel Nicolaus raised their target price on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday. HC Wainwright boosted their price target on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $114.92.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $92.29 on Thursday. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $109.28. The stock has a market capitalization of $5.57 billion, a price-to-earnings ratio of -192.27 and a beta of 0.49. The company has a 50-day simple moving average of $93.40 and a 200-day simple moving average of $79.18. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.98%. The business’s revenue was up 49.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.00 EPS. On average, analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Activity

In related news, SVP Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $99,994.40. Following the completion of the transaction, the senior vice president directly owned 4,503 shares of the company’s stock, valued at approximately $465,159.90. The trade was a 17.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Patrick J. Heron bought 131,425 shares of the firm’s stock in a transaction on Friday, January 23rd. The shares were purchased at an average price of $68.48 per share, for a total transaction of $8,999,984.00. Following the completion of the transaction, the director owned 459,010 shares of the company’s stock, valued at $31,433,004.80. This represents a 40.12% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 45,136 shares of company stock valued at $4,352,029 in the last quarter. Insiders own 14.36% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MIRM. Janus Henderson Group PLC grew its stake in Mirum Pharmaceuticals by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after acquiring an additional 1,067,722 shares during the last quarter. Eventide Asset Management LLC grew its position in shares of Mirum Pharmaceuticals by 4.4% in the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after purchasing an additional 110,485 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Mirum Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock valued at $205,065,000 after purchasing an additional 50,720 shares during the last quarter. State Street Corp increased its stake in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Mirum Pharmaceuticals by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock worth $112,196,000 after purchasing an additional 137,087 shares during the last quarter.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product growth — Mirum reported ~50% year-over-year revenue growth driven by Livmarli and other drug sales, topping estimates and providing fundamental support for the stock. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrades/target raises — Stifel raised its price target to $125 (buy) and TD Cowen raised its target to $117 (buy), signaling continued analyst confidence and suggesting meaningful upside from current levels. Analyst Coverage (Benzinga)
• Neutral Sentiment: Analyst consensus roundup — several coverage notes were published (13-analyst roundup) that summarize mixed but generally constructive views; useful for gauging street positioning. 13 Analysts Have This To Say About Mirum Pharmaceuticals
• Neutral Sentiment: Other analyst moves — RBC and Citizens JPM trimmed targets modestly but kept outperform/market outperform ratings, indicating conviction despite small PT adjustments. RBC Commentary (Street Insider)
• Neutral Sentiment: Earnings call and transcripts available — management commentary from the Q4 call provides more detail on commercialization cadence and upcoming catalysts; worth reviewing for guidance tone and commercialization cadence. Q4 2025 Earnings Call Transcript (Fool)
• Negative Sentiment: EPS miss — Mirum reported a GAAP loss of ($0.11) vs. consensus of $0.02, a notable EPS miss that can weigh on sentiment despite the revenue beat. Mirum Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Guidance mixed — management set FY2026 revenue guidance of $630–$650M vs. a consensus near $646M, leaving limited upside to Street expectations and creating potential downside if execution slips. Press Release / Guidance (Company PDF)
• Negative Sentiment: Short-term pullback coverage — commentary and retail pieces explaining intra-day/short-term weakness (e.g., articles on why MIRM was down) may amplify volatility even as fundamentals improve. Why MIRM Stock Is Down 13.46% (AAII)

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.